McKesson (MCK) announced that it signed a definitive agreement to acquire a controlling interest in Prism Vision. McKesson will purchase an 80% interest for approximately $850M. Prism Vision physicians will continue to retain a 20% interest in Prism Vision. Following completion of the transaction, Prism Vision will be consolidated within McKesson’s U.S. Pharmaceutical segment. The transaction is subject to customary closing conditions, including necessary regulatory clearances. Upon closing, Prism Vision is anticipated to be approximately 20c to 30c accretive to McKesson’s adjusted EPS in the first 12 months, and 65c to 75c accretive by the end of the third year following the close of the transaction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- MCK Upcoming Earnings Report: What to Expect?
- McKesson price target lowered to $677 from $713 at Citi
- McKesson price target lowered to $650 from $680 at BofA
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- McKesson price target raised to $642, named a ‘Top Pick’ at Morgan Stanley
Questions or Comments about the article? Write to editor@tipranks.com